LifeSci Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $6
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.
LifeSci Capital initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $6.